Spire by St Brides

Tiziana Life Sciences #TILS – Exec Chairman Gabriele Cerrone purchases more shares

New York/London, 14 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on the 13 January 2020 it was informed that on that date, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, […]

Open Orphan #ORPH – Second Closing of the hVIVO Offer, No extension of the Offer

Second Closing of the Offer No extension of the Offer Introduction On 9 December 2019, the boards of Open Orphan and hVIVO announced that they had reached agreement on the terms of a recommended all-equity offer for the entire issued and to be issued share capital of hVIVO (the “Offer”). Under the terms of the Offer, hVIVO […]

Cadence Minerals #KDNC – Macarthur Minerals (TSX-V: MMS) Q4 Update & Early 2020 Update on W Australia Projects, “Iron Ore the Commodity for 2020”.

Cadence Minerals (AIM/NEX: KDNC; OTC: KDNCY) is pleased to note today’s Q4 update from Macarthur Minerals (TSX-V: MMS) (“Macarthur”) on it’s flagship Lake Giles Iron Project, along with very positive early exploration results across Macarthur’s iron ore, gold, nickel and cobalt projects in Western Australia. Cadence Minerals Holding in Macarthur Cadence holds approximately 7.4% of […]

Tiziana Life Science (Nasdaq: TLSA / AIM: TILS) – Proposed Cancellation from AIM

New York/London, 13 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that it has appointed advisers in relation to an intended redomicile of the Company to Bermuda which is anticipated to occur by Q2-2020, as a consequence of the redomicile the Company will not be seeking to re-admit its […]

Ken Baksh – Quarterly Investment Report Q1 2020

Investment Strategy /Asset Allocation-First Quarter 2020 Any reference to benchmark should be tailored to individual client preference. These could, for instance, be 1) Absolute return based. 2) Cash/ LIBOR/SONIA, or equivalent, based (0.70%). 3) Inflation based. (UK CPI 1.5% November). 4) Index based (FTSE 100, FTSE All-Share, MSCI, S&P etc.). 5) Peer group based (Private […]

Irish Independent – Open Orphan signs ‘significant’ revenue generating contract

by Ellie Donnelly Open Orphan, a Europe-focused pharma services company specialising in rare disease and so-called orphan drugs, has signed a contract with a German-based research-driven pharmaceutical company. Open Orphan said the contract guarantees “significant” annual income, with work under the deal to commence this month. This contract will see Venn Life Sciences, part of […]

Tiziana Life Sciences #TILS – Phase 1 Clinical Data Demonstrating Oral Treatment with Foralumab is Well-tolerated in Healthy Volunteers

New York/London, 9 January 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory diseases and cancers, is pleased to report completion of a Phase 1 clinical study of Foralumab, a fully human anti-CD3 monoclonal antibody (“mAb”), in healthy subjects. The proprietary oral formulation, comprising the lyophilized and […]